An alternative strategy that has been evaluated in pre-clinical studies involves the use of CAR-T cells engineered to release an immune checkpoint blockade single-chain variable fragment (scFv), which was found to enhance the survival of PD-L1 positive tumour-bearing mice [43]. Here, CD274 is linked to neoplasm.